Study guide

18.2 Monitoring Methods and Source Review

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

18.2 Monitoring Methods and Source Review

Key Takeaways Explain This Topic AI

SDV compares reported data with source; SDR assesses broader conduct and context.

Remote, on-site and central methods have complementary strengths.

ICH does not prescribe a universal fixed SDV percentage.

Last updated: October 2026

Monitoring Methods and Source Review

On-site monitoring can be important within a justified risk-proportionate strategy; E6(R3) does not require the same on-site approach for every trial. Rather than spending 100% of on-site time seated behind closed doors reviewing paper charts, the CRA focuses on physical inspections, investigator oversight evaluations, and observational verification:

Physical Facility & Pharmacy Inspection: Auditing investigational product storage facilities, verifying continuous temperature logger calibration, inspecting biological sample freezers (-80°C), and observing drug reconstitution procedures.

Observational Verification: Observing study staff conduct clinical assessments, verifying that specialized diagnostic equipment (e.g., calibrated spirometers or retinal scanners) is operated properly.

Investigator Engagement: Conducting in-depth face-to-face debriefs with the Principal Investigator to assess protocol comprehension, clinical decision-making, and supervisory oversight.

Targeted SDV & In-Depth Source Data Review (SDR).

Remote Monitoring

Remote monitoring involves off-site activities conducted by field CRAs, focusing on individual site data and documentation with a focus on that site; roles and analytical responsibilities can overlap:

Reviewing electronic trial master file (eTMF) and investigator site file (ISF) regulatory submissions.

Reviewing electronic Case Report Form (eCRF) completion timeliness and issuing data queries.

Inspecting direct electronic health record (EHR) records remotely where institutional security policies and participant consent permit secure off-site access.

Modality Comparison Matrix

Operational Feature Centralized Monitoring Remote Monitoring (CRA) On-Site Monitoring (CRA)

Primary Performer Central Monitors / Biostatisticians / Data Scientists Field CRA / Remote Site Monitor Field CRA (In-Person)

Data Perspective Population-level, aggregate data across all trial sites Single-site data and documents Single-site primary sources and physical assets

Analytical Tools Advanced statistical algorithms, KRI dashboards, heatmaps EDC query modules, eTMF portals, remote EHR portals Physical chart review, pharmacy inspection, direct interview

Primary Strengths Detects fraud, digit preference, outlier sites, safety trends Efficient routine tracking, rapid query resolution Assesses physical storage, PI oversight, clinical technique

Source Data Verification (SDV) vs. Source Data Review (SDR)

A useful CCRA distinction is the distinction between Source Data Verification (SDV) and Source Data Review (SDR) . These terms are not interchangeable.

Documenting a monitoring plan

A plan should explain the chosen strategy, responsibilities, activities, methods, rationale, timing, escalation and how follow-up is documented. Define which data/processes receive review and how the intensity may change as evidence accumulates. Critical consent, eligibility, safety, dosing and endpoint processes deserve particular attention, but ICH does not prescribe one universal 100% SDV list or first-three-participants rule .

For an illustrative trial, a sponsor might verify every primary endpoint and sample lower-risk transcribed fields. Another justified strategy may use different coverage supported by electronic controls and central review. The site still must obtain consent and follow every applicable protocol requirement for every participant. Risk-based monitoring changes assurance methods, not the underlying participant protections.

A risk trigger should lead to a proportionate investigation, not an automatic accusation. Missing records, low AE rates or unusual digits can reflect late entry, rounding, different participant populations, system configuration or misconduct. Check the denominator, exposure period and data completeness; obtain source evidence; document the explanation; and escalate unresolved concerns through the plan.

Key Risk Indicators (KRIs): Metrics, Operational Thresholds & Red Flags

Key Risk Indicators (KRIs) are predefined operational, safety, and data quality metrics evaluated dynamically during trial conduct to monitor risk levels at individual investigative sites. When a site's metric crosses a predefined mathematical threshold (defined in the trial plan with appropriate denominators and context), an automated alert is triggered, prompting immediate investigation.

Critical KRIs and Clinical Red Flags

Screening-to-Enrollment Ratio Outliers:

Metric: Number of participants enrolled divided by number screened.

Operational Red Flag: Across a global oncology trial, the average screening-to-enrollment ratio is 35% due to stringent biomarker exclusion criteria. Site 104 screens 15 subjects and successfully randomizes all 15 (100% conversion rate).

CRA Operational Interpretation: A 100% enrollment rate in a restrictive trial requires investigation in context. It may indicate that site staff may be enrolling ineligible subjects, misinterpreting exclusion criteria, or manipulating screening laboratory results. The responsible monitoring team should assess the signal and arrange proportionate follow-up, potentially including targeted source review or an on-site visit. A signal alone does not prove misconduct or require a formal audit.

Consent-to-Randomization Timing Discrepancies:

Metric: Time elapsed between documented informed consent signature and formal randomization in the IRT system.

Operational Red Flag: Subject 202 is randomized at 09:15 AM, while the signed informed consent form timestamp in the source notes is recorded as 11:30 AM on the same day.

CRA Operational Interpretation: Randomizing a participant or performing study assessments prior to obtaining signed informed consent conflicts with the applicable informed-consent process in E6(R3). Centralized audit trail analytics detect these timing anomalies automatically.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .